CLINICAL TRIAL: HALT-C

临床试验：HALT-C

• 批准号: 8166891
• 负责人: TIMOTHY ROSS MORGAN
• 金额: $ 0.57万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166891
• 关键词: Acquired Immunodeficiency Syndrome; Affect; Age; Alcoholism; Cessation of life; Chronic Hepatitis C; Cirrhosis; Clinic; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Funding; Grant; Health; Hepatitis C; Hepatitis C virus; Infection; Institution; Italy; Japan; Liver Failure; Liver diseases; Malignant neoplasm of liver; Patients; Research; Research Personnel; Resources; Source; Spain; United States National Institutes of Health; liver transplantation; men; problem drinker

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hepatitis C affects an estimated 4 million people in the U.S., with 30,000 new cases diagnosed annually (1-3). The hepatitis C virus (HCV) ranks second behind alcoholism among the causes of liver disease and is the leading reason for liver transplants (4-6). Health experts say the number of deaths from HCV may soon surpass the number attributed to AIDS (Mayo Clinic, Dec. 12, 1998). In fact, hepatitis C might be the most common cause of primary liver cancer in the developed world. In Italy, Spain, and Japan, at least half of liver cancers could be related to HCV (7). Chronic hepatitis C can cause cirrhosis, liver failure, and liver cancer (8). About 20 percent of patients develop cirrhosis within 10 to 20 years of the onset of infection (9). Men, alcoholics, patients with cirrhosis, people over age 40, and those infected for 20 to 40 years are more likely to develop HCV-related liver cancer (7).

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 据估计，丙型肝炎影响美国 400 万人，每年诊断出 30,000 例新病例 (1-3)。 丙型肝炎病毒 (HCV) 在导致肝病的原因中排名第二，仅次于酗酒，并且是肝移植的主要原因 (4-6)。 健康专家表示，HCV 死亡人数可能很快就会超过 AIDS 死亡人数（Mayo Clinic，1998 年 12 月 12 日）。 事实上，丙型肝炎可能是发达国家原发性肝癌的最常见原因。 在意大利、西班牙和日本，至少一半的肝癌可能与 HCV 有关 (7)。 慢性丙型肝炎可导致肝硬化、肝功能衰竭和肝癌 (8)。 大约 20% 的患者在感染后 10 至 20 年内发展为肝硬化 (9)。 男性、酗酒者、肝硬化患者、40 岁以上的人以及感染 20 至 40 年的人更有可能患上 HCV 相关肝癌 (7)。